<DOC>
	<DOC>NCT01852058</DOC>
	<brief_summary>This study will evaluate the long-term safety and efficacy of onabotulinumtoxinA for the treatment of urinary incontinence due to neurogenic detrusor overactivity in patients who successfully completed Study 191622-120.</brief_summary>
	<brief_title>A Long-Term Extension Study of OnabotulinumtoxinA for Urinary Incontinence Due to Neurogenic Detrusor Overactivity</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Successfully completed participation in Study 191622120 Aged ≥ 5 years to ≤ 17 years at the time of entry into Study 191622120 Regularly using clean intermittent catheterization to empty the bladder Myasthenia gravis, EatonLambert syndrome, or amyotrophic lateral sclerosis Current or planned use of a baclofen pump Current or planned use of an electrostimulation/neuromodulation device for urinary incontinence Use of an indwelling catheter for urinary incontinence instead of using clean intermittent catheterization to empty the bladder Previous or current use of botulinum toxin therapy of any serotype for any urological condition, or treatment with botulinum toxin of any serotype for any other condition since entering study 191622120</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>